Search - tctmd.com

Displaying 341 - 360 of 819

Sort: Relevancy | Date

Fixed-Dose Combo Therapy Slashes CVD Risk in Primary Prevention

News Conference News ESC 2021

Fixed-Dose Combo Therapy Slashes CVD Risk in Primary Prevention

Michael O'Riordan

August 31, 2021

2021 ESC/EACTS Valve Guidelines Unveil TAVI/SAVR Age Cutoffs and Earlier Care

News Conference News ESC 2021

2021 ESC/EACTS Valve Guidelines Unveil TAVI/SAVR Age Cutoffs and Earlier Care

August 31, 2021

STEP Trial Supports Lower BP Goal in Older Patients With Hypertension

News Conference News ESC 2021

STEP Trial Supports Lower BP Goal in Older Patients With Hypertension

August 30, 2021

In ACS, Clopidogrel Monotherapy After 1-Month DAPT Falls Short: STOPDAPT-2 ACS

News Conference News

In ACS, Clopidogrel Monotherapy After 1-Month DAPT Falls Short: STOPDAPT-2 ACS

August 30, 2021

Amulet IDE: LAA Occluder Performs Well Against Watchman

News Conference News ESC 2021

Amulet IDE: LAA Occluder Performs Well Against Watchman

August 30, 2021

IAMI: Influenza Vaccine Beneficial for Post-MI Patients

News Conference News ESC 2021

IAMI: Influenza Vaccine Beneficial for Post-MI Patients

Michael O'Riordan

August 30, 2021

LOOP and STROKESTOP: Impact of AF Screening May Hinge on Arrhythmia Burden

News Conference News ESC 2021

LOOP and STROKESTOP: Impact of AF Screening May Hinge on Arrhythmia Burden

August 29, 2021

Massive SSaSS Study Shows Switch to Salt Substitute Cuts Stroke, CVD

News Conference News ESC 2021

Massive SSaSS Study Shows Switch to Salt Substitute Cuts Stroke, CVD

Michael O'Riordan

August 29, 2021

New ESC HF Guidelines Showcase SGLT2 Inhibitors, Tafamidis, Vericiguat, and COAPT

News Conference News ESC 2021

New ESC HF Guidelines Showcase SGLT2 Inhibitors, Tafamidis, Vericiguat, and COAPT

August 28, 2021

MASTER DAPT: One Month's Enough in Patients at High Bleeding Risk

News Conference News ESC 2021

MASTER DAPT: One Month's Enough in Patients at High Bleeding Risk

August 28, 2021

EMPEROR-Preserved: Empagliflozin Improves Outcomes in HFpEF

News Conference News ESC 2021

EMPEROR-Preserved: Empagliflozin Improves Outcomes in HFpEF

August 27, 2021

Heart Failure Patients With AF Benefit From Early Rhythm Control

News Conference News HRS 2021

Heart Failure Patients With AF Benefit From Early Rhythm Control

July 30, 2021

STROKE-VT: DOACs Cut Cerebrovascular Events After LV Arrhythmia Ablation

News Conference News HRS 2021

STROKE-VT: DOACs Cut Cerebrovascular Events After LV Arrhythmia Ablation

July 29, 2021

Timing of Mitral Surgery After Failed TEER Influences Outcomes

News Conference News TVT 2021

Timing of Mitral Surgery After Failed TEER Influences Outcomes

July 21, 2021

As New Guidelines Loom, CT Community Seeks to Fill Knowledge Gaps

News Conference News SCCT 2021

As New Guidelines Loom, CT Community Seeks to Fill Knowledge Gaps

Yael L. Maxwell

July 20, 2021

IRON-CRT: IV Iron Boosts LVEF, Cardiac Contractility in Deficient HF Patients

News Conference News ESC Heart Failure 2021

IRON-CRT: IV Iron Boosts LVEF, Cardiac Contractility in Deficient HF Patients

June 30, 2021

High Ischemic Risk and Bleeding Risk: A Delicate Balance Post-PCI

News Conference News EAS 2021

High Ischemic Risk and Bleeding Risk: A Delicate Balance Post-PCI

Michael O'Riordan

June 08, 2021

Central and Eastern Europe Failing to Achieve LDL Treatment Targets: DA VINCI

News Conference News EAS 2021

Central and Eastern Europe Failing to Achieve LDL Treatment Targets: DA VINCI

Michael O'Riordan

June 07, 2021

Lp(a) Not Associated With Ongoing Aortic Valve Calcification

News Conference News EAS 2021

Lp(a) Not Associated With Ongoing Aortic Valve Calcification

Michael O'Riordan

June 04, 2021

For High-Risk Patients Getting Evolocumab in Europe, Other Meds Fall Short

News Conference News EAS 2021

For High-Risk Patients Getting Evolocumab in Europe, Other Meds Fall Short

Michael O'Riordan

June 03, 2021

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.